Related Experiment Videos
Short-course cefotaxime compared with five-day co-amoxyclav in acute otitis media in children
P Gehanno1, M Taillebe, P Denis
1Hôpital Bichat, Paris, France.
Insights
A one-day injectable cefotaxime course showed similar efficacy to a five-day oral co-amoxyclav regimen for acute otitis media in children. Cefotaxime offered significantly better tolerance with fewer side effects.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Acute otitis media (AOM) is a common childhood infection.
- Conventional antibiotic treatments for AOM often involve multi-day oral courses.
- Optimizing antibiotic therapy for AOM in children is crucial for efficacy and tolerability.
Purpose of the Study:
- To compare the efficacy and tolerance of a short-course injectable cefotaxime versus a standard oral co-amoxyclav regimen for AOM in children.
- To evaluate the safety profile of both treatment regimens.
- To determine if a single-day injectable antibiotic is a viable alternative for AOM treatment.
Main Methods:
- A randomized, multicentre prospective study.
- 116 pediatric patients (3 months to 12 years) with AOM were enrolled.
- Comparison of one-day injectable cefotaxime versus five-day oral co-amoxyclav.
Main Results:
- No significant difference in treatment efficacy was observed between cefotaxime and co-amoxyclav groups.
- Significantly better tolerance was noted for cefotaxime.
- 22% of children on co-amoxyclav experienced side effects, compared to none in the cefotaxime group (P=0.0007).
Conclusions:
- Short-course injectable cefotaxime is an effective treatment for acute otitis media in children.
- Cefotaxime demonstrates superior tolerability and safety compared to oral co-amoxyclav.
- Injectable cefotaxime represents a valuable alternative to conventional AOM treatment regimens.
Abstract:
This randomized, multicentre prospective study was undertaken to compare the efficacy and tolerance of a one day course of injectable cefotaxime with a five day oral course of co-amoxyclav (amoxycillin plus clavulanic acid) in the treatment of acute otitis media in children. The study was conducted in 116 patients between the ages of three months and 12 years. No significant difference in efficacy was observed between the two treatment groups, but tolerance to the treatments differed significantly. There were no unwanted side-effects in the cefotaxime group whereas 22% of children in the amoxycillin plus clavulanic acid group suffered side-effects (P 0.0007). Short-course antibiotic therapy with cefotaxime appears to be a valuable alternative to conventional treatment regimens for acute otitis media in children.